Purpose. Systane® Lubricating Eye Drops (Alcon Forth Worth, Inc.) contains the PEG400/PG and the gelling agent hydroxypropyl-Guar (HP-Guar) that is believed to mimic the mucin layer of the tear film and it was designed to provide patient relief by means of longer retention time on theocular surface. We evaluated Systane in an open trial in patients complaining of moderate symptoms. Methods. A total of 50 subjects were enrolled (age 57.6 + 15.4; 40 women, 10 men) ; inclusion criteria were based on tear break-up time (TBUT) < 10 sec without corneal epithelial staining. Six symptoms of ocular irritation were rated on a four-point scale. Conjunctival hyperemia was graded. Patients were instructed to instill Systane four times a day for four weeks. Satisfaction with the product was rated at the end of the study. Media of results in both eyes was considered for statistical evaluation; the Wilcoxon test for paired data was applied, p< 0,05 was considered as statistically significant. Results All subjects regularly instilled Systane and completed the follow-up; results are expressed baseline vs endpoint. Significant reduction was demonstrated for ocular irritation symptom scores (1.44 vs 0.94, p 0.0001) while improvement was shown for patient’s satisfaction score (3.41 vs 3.94, p 0.0001) and TBUT (6.9 + 0.9 vs 8.5 + 1.5 sec, p 0.0001). A significantly increased proportion of patients with normal conjunctival injection (10 vs 22, results in %, p 0.01) was observed after one month follow up. Conclusions. Systane proved effective in reducing the symptoms of dry eye and it was overall well accepted. This finding is likely to be related with improved stability of tear film, due to the protective viscous layer bound to the corneal surface.

ONE MONTH THERAPY WITH SYSTANE IMPROVES OCULAR SURFACE PARAMETERS IN DRY EYE PATIENTS

VERSURA, PIERA;PROFAZIO, VINCENZO;CAMPOS, EMILIO
2007

Abstract

Purpose. Systane® Lubricating Eye Drops (Alcon Forth Worth, Inc.) contains the PEG400/PG and the gelling agent hydroxypropyl-Guar (HP-Guar) that is believed to mimic the mucin layer of the tear film and it was designed to provide patient relief by means of longer retention time on theocular surface. We evaluated Systane in an open trial in patients complaining of moderate symptoms. Methods. A total of 50 subjects were enrolled (age 57.6 + 15.4; 40 women, 10 men) ; inclusion criteria were based on tear break-up time (TBUT) < 10 sec without corneal epithelial staining. Six symptoms of ocular irritation were rated on a four-point scale. Conjunctival hyperemia was graded. Patients were instructed to instill Systane four times a day for four weeks. Satisfaction with the product was rated at the end of the study. Media of results in both eyes was considered for statistical evaluation; the Wilcoxon test for paired data was applied, p< 0,05 was considered as statistically significant. Results All subjects regularly instilled Systane and completed the follow-up; results are expressed baseline vs endpoint. Significant reduction was demonstrated for ocular irritation symptom scores (1.44 vs 0.94, p 0.0001) while improvement was shown for patient’s satisfaction score (3.41 vs 3.94, p 0.0001) and TBUT (6.9 + 0.9 vs 8.5 + 1.5 sec, p 0.0001). A significantly increased proportion of patients with normal conjunctival injection (10 vs 22, results in %, p 0.01) was observed after one month follow up. Conclusions. Systane proved effective in reducing the symptoms of dry eye and it was overall well accepted. This finding is likely to be related with improved stability of tear film, due to the protective viscous layer bound to the corneal surface.
9th International Congress IOIS Abstract Book
130
130
Versura P.; Profazio V.; Campos E.C.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/56051
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact